U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07036328) titled 'Transcranial Magnetic Stimulation to Slow Down Cognitive Decline in Alzheimer's Disease' on April 24.
Brief Summary: New amyloid-targeting drugs for Alzheimer's disease (AD) offer minimal or unclear efficacy and often cause adverse events, highlighting the need for new therapies. In recent years, repetitive transcranial magnetic stimulation (rTMS) has shown increasing success. A recent randomized, double-blind, sham-controlled, phase 2 demonstrated promising results from a 24-week rTMS treatment protocol targeting the precuneus. This brain region is considered a main hub of the human brain connectome and a prominent area of AD patho...